Indian Immunologicals Launches Mabella, a Measles and Rubella Vaccine for Children

Indian Immunologicals (IIL), a prominent vaccine manufacturer, has launched Mabella, a live-attenuated measles and rubella (MR) vaccine for children. This product launch marked the 25th anniversary celebrations of IIL's Human Biologicals Institute (HBI) in Udhagamandalam, Tamil Nadu. The vaccine, developed in an exclusive collaboration with the Polyvac Institute of Vietnam, has successfully undergone comprehensive human clinical trials, establishing its safety and efficacy.

Addressing Global Child Fatalities

Measles and rubella are responsible for approximately one lakh child fatalities each year worldwide. Mabella's introduction aims to control these deadly diseases, thereby addressing this critical global health concern.

HBI's Accomplishments

Since its inception in 1998, HBI has made significant strides in vaccine development. The institute developed India's first vero-cell rabies vaccine, Abhayrab, which allowed the Indian government to phase out the older, more painful nerve tissue vaccine. Since then, HBI has introduced several children's vaccines, including DPT, Pentavalent, TT, Hepatitis-B MR, and Td.

IIL's Commitment to Universal Immunization

According to IIL's managing director, K. Anand Kumar, the company has played a significant role as a primary supplier of human vaccines for the Indian government's universal immunization program. Deputy MD Priyabrata Pattnaik also emphasized IIL's robust infrastructure capabilities to meet national vaccine requirements.